Tea Protocol unveils Token Transparency Filing ahead of TEA launch on Aerodrome Ignition
Tea Protocol, a Layer 2 network built on the OP Stack, has published what it calls a B-1 Token Transparency Filing ahead of its TEA token launch. The filing, released via Blockworks, lays out the full blueprint: tokenomics, utility, governance structure, launch mechanics, and market commitments.
The token generation event is scheduled for 00:00 UTC on June 4, 2026, with Aerodrome serving as the launch venue through its Aero Ignition program.
What’s actually in the filing
The TEA token will have a total supply of 100 billion tokens. Roughly 20% of that supply will be unlocked and entering circulation at the time of the mainnet launch.
Here’s how the allocation breaks down: 28% goes toward incentives and airdrops, approximately 21% is earmarked for ecosystem governance, around 18% is reserved for protocol development, and roughly 16% is set aside for early supporters and advisors.
Annual inflation for TEA emissions is capped at 2%, managed by the TEA Association and its DAO.
Tea Protocol has raised approximately $19.9 million through seed and public sale rounds leading up to the TGE. A public sale on CoinList is planned for late 2025, which would precede the June 2026 launch.
The open-source angle
Tea Protocol’s emission model ties token rewards directly to developer activity. Rather than distributing tokens based on trading volume or liquidity provision alone, the system is designed to route value toward the people actually writing and maintaining code.
Aerodrome partnership and liquidity mechanics
Aerodrome, the leading DEX on the Base ecosystem, will act as both launch venue and liquidity partner for the TEA token. Liquidity incentives through the Aero Ignition program are set to begin voting around May 28, 2026, roughly a week before the TGE.
What this means for investors
The 20% circulating supply at launch means approximately 20 billion TEA will be tradeable from day one. The 2% annual inflation cap positions TEA as relatively conservative compared to many DeFi tokens that have historically printed supply at far more aggressive rates.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
